Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy and safety of PARP inhibitors for maintenance treatment of ovarian cancer, regardless of BRCA or HRD status: a comprehensive updated meta-analysis.

Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology - 1 Dec 2023

Li Yanhui

Abstract excerpt

Without taking into account existing biomarkers like genetic mutations (BRCA mutation, Homologous recombination deficiency) with advanced ovarian cancer (OC), the overall survival (OS), progress-free survival (PFS) of the aggregate all groups that have been classified were hazard ratio (HR): 0.72, 95% confidence intervals (CI): 0.66-0.79 and HR: 0.48, 95%CI: 0.44-0.52, respectively. Meanwhile, the OS and PFS of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Ovarian Epithelial
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ovarian Neoplasms

Share to Poly(ADP-ribose) Polymerase Inhibitors

Source

Identifiers

PMID: 36729640
DOI: 10.1080/01443615.2023.2171282

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy and safety of PARP inhibitors for maintenance treatment of ovarian cancer, regardless of BRCA or HRD status: a comprehensive updated meta-analysis.PMID 36729640Read ↗

Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA MutationsSemantic proximity Read ↗

Efficacy and safety analysis of PARP inhibitors combined with drugs for primary and relapsed ovarian cancer: A meta-analysis of randomized controlled trialsSemantic proximity Read ↗

Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current statusSemantic proximity Read ↗

Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancerSemantic proximity Read ↗

Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancerSemantic proximity Read ↗

PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage RepairSemantic proximity Read ↗

Role of PARP inhibitors beyond BRCA mutation and platinum sensitivity in epithelial ovarian cancer: a meta-analysis of hazard ratios from randomized clinical trials.Semantic proximity Read ↗

Prevalence of Homologous Recombination Deficiency in First-Line PARP Inhibitor Maintenance Clinical Trials and Further Implication of Personalized Treatment in Ovarian CancerSemantic proximity Read ↗

Poly (ADP-ribose) polymerase (PARP) as target for the treatment of epithelial ovarian cancer: what to know.Semantic proximity Read ↗

PARP Inhibitors in Ovarian Cancer: A ReviewSemantic proximity Read ↗

Therapeutic applications of PARP inhibitors in ovarian cancerSemantic proximity Read ↗

PARP inhibitors: a tsunami of indications in different malignancies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.